dc.description.abstract | Background: Inflammatory processes have a central role in Parkinson's disease.
In Parkinson's, there is progressive dopaminergic nerve degeneration in the
substantia nigra α-synuclein aggregated increases microglial activation and
stimulates the secretion of inflammatory molecules thereby triggering
neuroinflammation that triggers oxidative stress and exacerbates dopaminergic
neurodegeneration. C-reactive Protein (CRP) and albumin can be used as
markers of systemic inflammation and oxidative stress in Parkinson's disease.
Increased CRP, decreased albumin levels, and increased C-reactive proteinalbumin
Ratio (CAR) are associated with increased severity of Parkinson's
disease.
Objective: To find out the relationship between rates of C-Reactive Protein (CRP),
albumin levels, and C-Reactive Protein-Albumin Ratio (CAR) with the severity of
Parkinson's disease based on the Hoehn and Yahr Scale.
Method: This research uses a cross-sectional design. Research subjects were
Parkinson's disease sufferers at the Neurology Polyclinic at Adam Malik Hospital,
Medan, and Network Hospital from November 2023 to July 2024 who met the
inclusion criteria. Assessment of the severity of the disease using Hoehn and Yahr
Scale. Measurements of CRP, albumin, and CAR levels were obtained from
patient blood samples. Data analysis using tests Mann Whitney.
Results: Of the 37 research subjects, the average age was 62.54 ± 8.74 years, the
majority were men (62.2%), the majority had a bachelor's degree (32.4%), civil
servant work (35.1%), Batak ethnicity (67, 6%), nutritional status norm weight
(89.2%), and the majority of Parkinson's disease severity was mild to moderate
(70.3%). Median CRP levels were 0.8 mg/L, albumin 4.3 g/dL, and CAR 0.18.
Based on test Mann Whitney There were significant differences in CRP, albumin,
and CAR levels between patients with severe Parkinson's disease and mildmoderate
Parkinson's disease with values of p<0.001, p=0.004, and p<0.001.
Conclusion: There are significant differences in CRP, albumin, and CAR levels
between patients with severe Parkinson's disease and mild-moderate Parkinson's
disease. | en_US |